Lifecare (LIFE)

[Halleluja]

Juhu. Kjempenyhet…

[Andyboi]

Hehe, når det kommer til Life, så ser jeg på en slik oppdatering uten ytterligere forsinkelser som en god nyhet

[Halleluja]

Hehe, ja . Får se om litt hvordan markedet velger å tolke denne.

[TekBot]

Lifecare AS prolongs and amplifies collaboration with Bath University

Lifecare is happy to announce that the collaboration with the Chemistry Department of Bath University, UK, has been prolonged and further amplified. This will ensure mutual beneficiary progress on the development of proprietary specific chemistry solutions for detection of glucose and additional analytes of interest based on the Sencell technology.
In addition, Lifecare has directly engaged, Dr. Jordan Edward Gardiner as a consultant. Dr. Jordan Edward Gardiner is the scientist responsible for the Lifecare developments at Bath University under the guidance of Prof. Tony James, a worldwide leading expert in organic sensor chemistry development.
The collaboration between Lifecare and Prof. Tony James research group has so far resulted in significant improvements in sensitivity and specificity of the chemistry composition for glucose detection used in Lifecares core and proprietary Sencell technology for diabetes management.
…

Vis børsmeldingen

The European Patent Office recently communicated its intention to issue a new patent for Lifecares improved system for the osmotic pressure based Sencell technology (NewsWeb). The expected patent will increase the scope of protection until 2038 and broaden the technology scope to include detection of several parameters in the interstitial fluid. Based on the prolonged and amplified collaboration, Lifecare expect to develop effective chemical compositions suitable for exploiting additional commercial opportunities for the Sencell technology, in addition to the core field of diabetes management.
“With this step, we ensure that the scope of Lifecares Sencell sensor development expands from glucose alone to other analytes, such as but not limited to lactate, fructose, and calcium”, says Joacim Holter Lifecare’s CEO. “This will help to collect complementary information for understanding the user’s metabolism and ultimately providing personalized guidance to maintain better glucose control and improve general health”.

This is Lifecare
Lifecare (LIFE) is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The company’s patented technology also has the potential for use in various biomarkers.

For further information, please contact:
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no +47 40 05 90 40
This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 22 June, 2021 at 08:15 CET.

Kilde

[TekBot]

Lifecare AS acquires Cantimed UG and broadens its biosensing capabilities

Bergen, Norway 24.06.21

Lifecare AS has acquired 100% ownership of the German company Cantimed UG, following a share purchase agreement with Nanoscale Systems Nanoss GmbH.
…

Vis børsmeldingen

The transaction includes a license ensuring Lifecare´s access to the patented Nano3DSense technology in the medical field. This implies a continuation of Lifecare’s license covering the field of diabetes originally established in 2018 – and in addition broadens the Lifecares license to cover the entire medical field. This is opening significant business opportunities for Lifecare to develope additional nanobiosensors. The transaction also gives Lifecare the right to sublicense the technology to third parties based on pre-approved conditions.

“The patented Nano3DSense technology is a key production method to miniaturize the Sencell sensing system, which will be based on highly sensitive micro-electronic mechanical systems and nano-cantilevers”, says Lifecare CSO Prof. Andreas Pfützner.
The combination of Lifecares proprietary Sencell technology and the Cantimed- licensed Nanos3DSense technology positions Lifecare as an innovative nanobiosensor company.

Cantimed will form the new operational basis of Lifecare in Germany as the development of Sencell and other various nanobiosensors based on Lifecares proprietary technologies evolves.
The transaction has a value of EUR 650 000, of which EUR 280 000 will be paid in cash on closing and the remaining EUR 370 000 will be paid within 24 months subject to and based on satisfaction of terms in the agreement.
“This transaction replaces Lifecares previous license at an originally agreed cost of total EUR 1,5 Million, limited to the field of diabetes”, says Joacim Holter, Lifecare CEO.
The ownership of Cantimed enables Lifecare to introduce its unique sensing system for glucose and many other analytes both in combination with the Sencell technology and as stand-alone nanobiosensors to cover a wide range of medical applications.

“In combination with the previously announced intention from the European Patent Office to grant Lifecare a new patent for the improved Sencell sensing system based on two chambers, and the extended cooperation with Bath University to develop chemistry solutions for additional analytes to fully use the improved osmotic-pressure based sensors, Lifecare is strategically well positioned to exploit the potential of the Nano3DSensing technology”, says Joacim Holter. “The implication of this transaction is important for Lifecare. Not only does it strengthen the ownership to our basic developments, but it also positions Lifecare as a leading company within the field of nanobiosensor developments”.

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The company’s patented technology also has the potential for use in various biomarkers. Lifecare AS is listed on Euronext Growth (LIFE).

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 24 June, 2021 at 08:30 CET.

Kilde

[Salamis]

LC eide altså 50% av aksjene i Cantimed fra 2018 av gjennom et oppkjøp organisert gjennom IMS, som er skandaleselskapet til den arresterte Aleksander Vucak, som igjen er koblet til wirecard skandalen.

Fra 2019: Som ledd i strategisk omstrukturering har selskapet overtatt 50%
av aksjene i cantiMED UG (Tyskland), fra selskap tilknyttet Lifecare’ Chief
Scientific Officer.

Fra e24: Han og det øvrige styret i Lifecare hadde kjent til IMS siden 2018 gjennom CantiMed UG, et selskap som Lifecare eier 50 prosent av.

De fortsetter tendensen i å kjøpe opp selskaper som ansatte eier eller har ledende roller i, og de er fremdeles viklet inn i IMS skandalen.

[Evilfreud]

Høres ut som en effektiv måte å tømme selskapet for penger på.

[Andyboi]

Noen som vet hva som skjer? Fikk varsel om at den passerte 2,5 kr nå, hadde lagt denne foreløpige mislykkede traden i skuffen, men kan se ut som jeg ender i pluss

Er det HMONY-aksjonærer som flytter penger ?

[Andyboi]

Det kan ha noe med dette å gjøre:

Open Position – Leading Senior Scientist Nanotechnology Development

Open Position – Leading Senior Scientist Nanotechnology Development
Lifecare AS (lifecare.no) is a stock listed Norwegian company with operations in Germany (Rhine-Main Area and Northern Germany). The company is engaged in the development of innovative biosensors based on MEMS and NEMS technologies. Current flagship product is a very small implantable continuous glucose sensor with ultra-long duration of use for patients with Diabetes mellitus. Lifecare is currently in the process to establish a significant operational infrastructure for R&D and manufacturing of nanoscale biosensors in Mainz and Oldenburg (Oldb). You will accompany this process in a responsible position.
‍

These tasks await you

•  Taking responsibility for setting up a new R&D infrastructure for FEBID applications (SEM microscopes etc.) at our operational         headquarter in Germany (Rhine-Main-Area)
  

•  Independent planning, control and execution of development projects
  

•  development of high precision FEBID processes for multiple MEMS components
  

•  Transfer of new machining processes in production
  

•  Documentation, communication and presentation of project results, as well as close coordination with the senior management
  

•  Close cooperation with internal and external expert teams, domestic and foreign institutes, partners and customers
  

Our requirements are:

Very good degree in physics, materials science, nanotechnology, engineering or similar with a physical or technical focus, ideally followed by a PhD
Experience in the development of highly complex systems / processes in the context of a doctorate / postdoc activity or first professional experience in industry
Knowledge in one or more of the following areas is advantageous: semiconductor physics, optics technology, surface processing / optics processing, micro- and nano-structuring, lithography, nano fabrication, FEBID, structuring technology, thin film technology, process development, optimisation, vacuum technology
Experience in clean room desirable
Processing of Nanomaterials
Robotic fabrication environment in the SEM, incl. control and automation
In-situ electromechanical characterisation
FIB and EBiD processes
Merging all process steps into a novel 3D nano-printing process for nanoscale sensors
Experience in the forward-looking transfer of research results into marketable products
Strong communication, assertiveness and teamwork skills
Independent working style, analytical thinking and creativity
Pleasure and willingness to familiarise yourself with new topics
Very good written and spoken German and English skills
We offer:

•  an attractive compensation package beyond standard industry compensations
  

•  other compensations according to German standards (healthcare, vacation days, capital-forming benefits, etc.)
  

Please send your full application to Prof. Andreas Pfützner

Tel.: +491726296117, mail: andreas.pfuetzner@lifecare.no, web: www.lifecare.no

[TekBot]

The European Patent Office grants new Lifecare patent

Bergen, Norway 03.08.21

The European Patent Office (EPO) has as expected decided to grant Lifecare a new patent for an updated sensor measuring system. The now approved patent expands Lifecare’s protection in time and scope.
…

Vis børsmeldingen

As announced in Lifecare’s press release 25.03.21, the EPO by then intended to grant this patent, about an “interstitial fluid osmotic pressure measuring device system and method”. This protection is now confirmed and ensured until 2038. The new patent represents a fundamental addition to Lifecare’s IP and an important next step utilizing the Sencell technology from research and development to a broader commercialization. The sensor design described in the new patent intends to improve signal amplitude, increase the accuracy of subcutaneous glucose assessment, and to improve sensor longevity and robustness against environmental interferences. This new sensor version is also suitable for measurement of other analytes, in addition to glucose.

“As mentioned in March, this European patent will strengthen our position for correct and continuous monitoring of blood sugar, in people with diabetes. In addition, a scope of other analytes useful in both a medical and lifestyle perspective can now be realized. The updated system, which has the size of a grain of rice, will be used in our upcoming human pilot studies already approved by German regulatory authorities,” says Joacim Holter, CEO Lifecare

Patent broadens the scope and application of the Sencell technology

“The patent opens the opportunities to expand the use of the Sencell technology.” Says Prof. Andreas Pfützner, Lifecare’s Chief Scientific Officer and one of the patent inventors. “It increases the scope of protection to include measurement of many parameters in the interstitial fluid, including but not limited to lactate, fructose, and calcium and many other biomarkers.”

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The company’s patented technology also has the potential for use in various biomarkers. Lifecare AS (Ltd.) is listed on Euronext Growth (LIFE).

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 03.08.2021 at 15:40 CET.

Kilde

[Andyboi]

Dette må vel være en pump og dump, har vel vært forventet siden vinter?

Fikk lempa ut lytteposten min, pumpes vel før emisjon?

[TekBot]

Interim report first half 2021

Bergen, Norway 05.08.21

Please find attached Lifecare AS’ unaudited Interim Report for first half 2021. The report is also available on https://www.lifecare.no
…

Vis børsmeldingen

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 05.08.2021 at 06:00 CET.

Kilde

[Andyboi]

Her brennes det cash, ja. Gribbene står vel klare til å delta i en svært utvannende emisjon?

Pengene fortsetter å renne ut av Lifecare

[TekBot]

Notification of Extraordinary General Meeting regarding a potential private placement of new shares and information regarding acquisition of laboratory

Bergen, Norway 27.08.21

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
…

Vis børsmeldingen

Summary

Today the Board of Directors (the “Board”) of Lifecare AS (the “Company” or “Lifecare”) has passed the following resolutions:

• convening an Extraordinary General Meeting to be held on 10 September 2021 to approve a board authorization for a share capital increase of up to 25% of the Company’s current share capital (the “Board Authorisation”).
• approving the term sheet for acquiring the laboratory of Pfützner Science & Health Institute GmbH and the Board’s report and declaration in line with section 3-8 of the Norwegian Limited Liabilities Companies Act for such acquisition.

Notice of Extraordinary General Meeting is enclosed to this announcement. The Board’s report and declaration, and confirmation from the Company’s auditor, in line with section 3-8 of the Norwegian Limited Liabilities Companies Act are published at www.lifecare.no/3-8reports

1. Contemplated private placement of new shares

Lifecare has engaged Carnegie AS as bookrunner and manager (the “Manager”) to advise on and effect a contemplated private placement of new shares with gross proceeds from NOK 17.8 million and up to NOK 40 million (the “Private Placement”). The number of new shares to be issued in the Private Placement will depend on the final subscription price in the Private Placement which will be determined by the Board in consultation with the Manager following a bookbuilding process.

Subject to completion of the Private Placement, the net proceeds will be used for: (i) Further research, development and clinical studies of the implantable sensor Sencell towards CE mark, (ii) strengthening the Company’s balance sheet to ensure financial capacity and flexibility to pursue growth opportunities, (iii) working capital as well as for general corporate purposes, and (iv) continue to develop the organization and internationalize the Company.

Completion of the Private Placement will inter alia be conditional upon i) all necessary corporate resolutions being validly made by the Company, including without limitation, the extraordinary general meeting approving the Board Authorisation and the Board resolving to allocate and issue the new shares pursuant to the Board Authorisation and (ii) the registration of the share capital increase in the Company pertaining to the new shares in the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret) having taken place.

Several of the Company’s major shareholders have pre-committed to subscribe for new shares in the contemplated Private Placement without reservation on terms or request for pre-commitment fee:

Teigland Eiendom AS (largest shareholder - 18.2%) - NOK 10 million
Lacal AS (second largest shareholder - 13.1%) - NOK 6 million
Spit Air AS (eighth largest shareholder – 2.2%) - NOK 1 million
Patricia Sandquist (seventh largest shareholder – 2.2%) - NOK 0.8 million

The Board has considered alternative structures for the raising of new equity. Following careful considerations, the Board is of the view that it will be in the common interest of the Company and its shareholders to raise equity through a private placement setting aside the pre-emptive rights of the shareholders. By structuring the transaction as a private placement, the Company will be in a position to raise capital in an efficient manner. In addition, the Private Placement will be subject to marketing through a publicly announced book building process. By this, a market-based subscription price will be achieved. Subject to completion of the Private Placement, the Company will also consider whether to commence a repair offering towards the existing shareholders who do not participate in the Private Placement.

2. Acquisition of Laboratory. From customer to full control.

Lifecare has signed a term sheet to acquire the laboratory of Pfützner Science & Health Institute GmbH (the “Lab”) for a total consideration of up to Euro 1.175 million of which Euro 100,000 will be paid in cash, Euro 300,000 will be settled in new shares in Lifecare, and the remaining part of the consideration, up to EUR 775,000 will be settled through a profit-based combined cash and share earn-out within 2026.

• “For Lifecare, this acquisition means that the ongoing R&D process will be far more predictable and effective”, says Joacim Holter, Lifecare CEO.

Ensuring control of development is expected to represent immediate benefits:

• Significant cost savings.
• Increased control. Lifecare will end being a customer of the Lab and get in a position to exercise control for development of the Sencell development and thereby be able to fully control the operational abilities and priorities.
• Increased capacity and flexibility. Lifecare will be able to utilize the Lab´s capacity and customer orders according to its own needs.
• Better profitability. The Lab has recurring revenue from third parties, based on already active service agreements 2021 and 2022.
• Strengthened relationship. The affiliation of Prof. Pfützner, who is vital for the Lab as well as for Lifecare´s Sencell development as the company’s CSO, will partly be transformed from consultant selling services to Lifecare, into a combination of consultancy and employment. Prof. Pfützner and Lifecare agree to continue this transformation with the aim to establish the affiliation as a solely employment relationship in the future. Prof. Pfützner’s long term commitment to Lifecare AS will be strong due to the profit-based earn-out and payment in shares.

Lifecares’ acquisition of cantiMED UG, announced 24 June 2021 (renamed Nanobiosensors GmbH), includes a license ensuring Lifecare´s access to the patented Nano3DSense technology in the medical field. This implies a continuation of Lifecare’s license covering the field of diabetes, and in addition broadens the Lifecares license to cover the entire medical field.

By including the Lab into the Lifecare structure, as an integrated part of Nanobiosensors GmbH, Lifecare will enhance its operational abilities and ensure a dramatically improved capacity for R&D, wholly controlled by Lifecare.

This is Lifecare

Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The company’s patented technology also has the potential for use in various biomarkers. Lifecare AS is listed on Euronext Growth (LIFE).

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 27.08.2021 at 10:00 CET.

Kilde

[Salamis]

Er det noen igjen her som bryr seg om hva selskapet gjør…(?), jepp, de skal kjøpe enda et selskap som en av de ansatte eier…et «institute» denne gangen…storflotte greier

[Rockzolid]

Jeg har vært relativt negativ til Lifecare en god stund, med god grunn. De siste 6mnd er kursen ned 74%. Har tjent gode penger på aksjen tidligere. Nå er den på nivå med mars 2020 da Covid ble introdusert, og også på nivå med første handelsdag Lifecare hadde på børs i juli 2018.

I mellomtiden har utviklingen av Sencell gått fremover om ikke akkurat med stormskritt. Jeg tenker at dersom man har tro på Sencell som produkt og ikke er av den oppfatning at Lifecare ikke får hentet cash og dermed går enda mørkere tider i møte, så er kanskje ca nå en god tid å ta noen lodd.

[Aaleby]

Hvorfor kaste penger inn i det største jallacaset på børsen FØR emisjonen, som garantert kommer med en saftig rabatt?

[tubist92]

Pengene de henter inn nå går jo også rett ut igjen. De skal kjøpe et «institutt» fra en ansatt. Hvilke penger de skal bruke til drift og videre fremgang på cencell er uvisst.

Og la oss være ærlig; hadde cencell vært så fantastisk, hvorfor er det da INGEN store selskap som fatter interesse?

[Rockzolid]

Er ikke så sikker på at det vil bli gitt en så saftig rabatt fra nivået kursen befinner seg på nå, dvs ca kr 1,5. Folk snakker om kr 1 osv. Det har jeg ikke særlig tro på. Vi får se hva som skjer med kursutviklingen i løpet av uken og hva emi kursen blir satt til. Sier ikke at man skal gå all in nå, men å begynne å plukke litt tror jeg ikke er så dumt.

Når det gjelder Sencell så er produktet i hvert fall såpass lovende at de har mottatt støtte fra EU. Den henger så vidt jeg vet ganske høyt. Om andre selskaper fatter interesse eller ikke er vel ikke noe noen av oss med sikkerhet kan vite. Men på disse nivåene skal man vel ikke utelukke det 100%.

[Aaleby]

@Rockzolid

Er ikke så sikker på at det vil bli gitt en så saftig rabatt fra nivået kursen befinner seg på nå, dvs ca kr 1,5.

Skal være glad for at vi alle er forskjellige. Personlig har jeg null glede av å skyte penger inn i et selskap ledet av skruppelløse halvkriminelle som har beriket seg på naive småinvestorer.

Trade eller ikke. Kunne ikke fristet mindre. Som også er utfordringen med tanke på emisjonen; hvordan de vil lykkes i et marked som i stor grad skyr selskapet som pesten. Høyere enn dagens blir kursen hvert fall ikke.